Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Vätsketillförsel vid ketoacidos (DRINK) (DRINK)

5 november 2026 uppdaterad av: Centre Hospitalier Universitaire de Nice

Jämförelse av saltlösning och ringerlaktat hos patienter med svår diabetisk ketoacidos (DRINK): en dubbelblind randomiserad kontrollerad studie

Management of severe diabetic ketoacidosis is based on insulin therapy, correction of metabolic disorders and fluid resuscitation. Current recommendations recommend the first-line use of isotonic saline, whose composition is unbalanced, rich in chloride and sodium compared with plasma. Administration of large volumes of isotonic saline is associated with a risk of hyperchloremic metabolic acidosis and acute renal failure. Balanced solutions (e.g. Ringer Lactate) are solutions with a more balanced electrolyte composition close to that of plasma. They could therefore enable diabetic ketoacidosis to be resolved more quickly than isotonic saline, due to a lower risk of hyperchloremic acidosis. Preliminary data suggest a potential benefit of balanced solutions for fluid resuscitation of patients with severe diabetic ketoacidosis in terms of resolution of diabetic ketoacidosis, but no randomized controlled double-blind study to date has compared balanced solution vs. isotonic saline in this context.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

300

Fas

  • Fas 4

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Admission to emergency department or direct admission to ICU
  • Diagnosis of severe diabetic ketoacidosis requiring all the following criteria:
  • Blood or capillary glucose > 11 mmol/L
  • Ketonemia or ketonuria > 0
  • Venous or arterial pH < 7.30 or venous or arterial bicarbonate < 15 mmol/L
  • Volume of fluid administered before inclusion <1L

Exclusion Criteria:

  • Patients <18 years
  • Pregnant women
  • Patients under protection
  • Patients with a decision to withdraw life-sustaining therapy
  • Contraindication to isotonic saline or Ringer Lactate
  • Non-affiliation to social security

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Isoton koksaltlösning

Isotonic saline only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:

  • During the first hour of treatment:

    • In the event of systolic arterial hypotension (SAP<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.
    • In the absence of systolic arterial hypotension (SAP>90mmHg): administration of 1L over 1 hour.
  • Between 60 minutes and 8 hours of treatment :

    • 1L over 2 hours, repeated once, then 1L over 4 hours
    • Adjust fluid resuscitation according to clinical tolerance
  • After the first 8 hours:

    • 1L over 4h then 1L over 6h
    • Clinical re-evaluation according to standard of care in participating centers
Experimentell: Ringer Laktat

Ringer Lactate only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:

  • During the first hour of treatment:

    • In the event of systolic arterial hypotension (SAP<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.
    • In the absence of systolic arterial hypotension (SAP>90mmHg): administration of 1L over 1 hour.
  • Between 60 minutes and 8 hours of treatment :

    • 1L over 2 hours, repeated once, then 1L over 4 hours
    • Adjust fluid resuscitation according to clinical tolerance
  • After the first 8 hours:

    • 1L over 4h then 1L over 6h
    • Clinical re-evaluation according to standard of care in participating centers

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Resolution of diabetic ketoacidosis
Tidsram: at 24 hours

Compare fluid resuscitaiton with Ringer Lactate to isotonic saline on the resolution of diabetic ketoacidosis at 24 hours from admission to Intensive Care Unit (ICU) in patients with severe diabetic ketoacidosis.

Resolution of ketoacidosis allowing discharge from ICU, defined as the proportion of patients with the following three criteria at 24 hours from ICU admission :

  1. capillary or blood glucose < 11 mmol/L
  2. ketonemia < 0.6 mmol/l
  3. venous or arterial pH ≥ 7,30 or venous or arterial bicarbonate ≥ 18 mmol/L
at 24 hours

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Speed of resolution of metabolic disorders
Tidsram: at 48 hours

Compare fluid resuscitation with Ringer Lactate and isotonic saline solution on the speed of resolution of metabolic disorders in patients admitted to ICU for severe diabetic ketoacidosis.

Proportion of patients and number of hours ("Resolution free hours") within 48 hours of ICU admission with the following three criteria:

  1. capillary or blood glucose < 11 mmol/L
  2. ketonemia < 0.6 mmol/l
  3. venous or arterial pH ≥ 7,30 or venous or arterial bicarbonate ≥ 18 mmol/L
at 48 hours
Time of resolution of metabolic disorders
Tidsram: at 48 hours

Compare fluid resuscitation with Ringer Lactate and isotonic saline solution on the speed of resolution of metabolic disorders in patients admitted to ICU for severe diabetic ketoacidosis.

Time (in hours) from ICU admission to obtain one of the following three criteria:

  1. capillary or blood glucose < 11 mmol/L
  2. ketonemia < 0.6 mmol/l
  3. venous or arterial pH ≥ 7,30 or venous or arterial bicarbonate ≥ 18 mmol/L
at 48 hours
Assess the metabolic tolerance of Ringer Lactate compared to isotonic saline solution
Tidsram: through the end of study average 24 months

Assess the metabolic tolerance of Ringer Lactate compared to isotonic saline solution in patients admitted to ICU for severe diabetic ketoacidosis.

Occurrence of serious metabolic disorders during ICU stay, defined as :

  1. Kalemia < 3 mmol/L
  2. Natremia > 145 mmol/L
  3. Chloremia > 110 mmol/L
  4. Phosphoremia < 0.70 mmol/L
  5. Blood glucose < 3.8 mmol/L (i.e. 0.80 g/L)
  6. Persistent ketonemia/ketonuria 24 hours after ICU admission 2. Nature and volume (in liters) of fluid administered before inclusion and during the study period in each group 3. Protocol compliance (expressed as % of volume administered in each group)
through the end of study average 24 months
Assess the impact of Ringer lactate compared with isotonic saline on renal, neurological and cardiac complications
Tidsram: at 28 days

To assess the impact of Ringer lactate compared with isotonic saline on renal, neurological and cardiac complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis.

Occurrence of adverse events during ICU stay, defined as :

  1. Neurological disorders (Glasgow score)
  2. Acute renal failure (KDIGO classification)
  3. Cardiac disorders (supraventricular and ventricular rhythm disorders, acute coronary syndrome) 2. ICU and hospital length of stay 3. ICU mortality and Day-28 mortality
at 28 days
Assess the impact of Ringer lactate compared with isotonic saline on cardiac complications
Tidsram: at 28 days

To assess the impact of Ringer lactate compared with isotonic saline on cardiac complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis.

Occurrence of adverse events during ICU stay, defined as :

  • Cardiac disorders (supraventricular and ventricular rhythm disorders, acute coronary syndrome)
  • ICU and hospital length of stay
  • ICU mortality and Day-28 mortality
at 28 days
Assess the impact of Ringer lactate compared with isotonic saline on renal complications
Tidsram: at 28 days

To assess the impact of Ringer lactate compared with isotonic saline on renal, complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis.

Measure acute renal failure with KDIGO classification.

The Kidney Disease: Improving Global Outcomes (KDIGO) classification system stratifies acute kidney injury (AKI) into levels of severity, determined by changes in serum creatinine (SCr) / estimated creatinine clearance (eCCl), as well as changes in urine output. The strata of severity of AKI can be reached by meeting the criteria for changes in SCr / eCCl or changes in urine output. There are three levels of severity, with level 1 being the least severe and level 3 the most severe.

No cut-off for the study

at 28 days
Assess the impact of Ringer lactate compared with isotonic saline on neurological complications
Tidsram: at 28 days

To assess the impact of Ringer lactate compared with isotonic saline on neurological complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis.

Measure Neurological disorders with Glasgow score. The Glasgow Coma Scale (GCS) is used to objectively describe the extent of impaired consciousness in all types of patients. The scale rates patients on three aspects of reactivity: eye opening, motor responses and verbal responses. It ranges from 3 (coma) to 15 (no disturbance of consciousness). No cut-off for the study.

at 28 days

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

26 november 2025

Primärt slutförande (Beräknad)

1 december 2027

Avslutad studie (Beräknad)

1 juli 2028

Studieregistreringsdatum

Först inskickad

8 juli 2024

Först inskickad som uppfyllde QC-kriterierna

2 augusti 2024

Första postat (Faktisk)

7 augusti 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

10 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

5 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 22-API-03

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .